Connor Clark & Lunn Investment Management Ltd. Has $7.32 Million Holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

Connor Clark & Lunn Investment Management Ltd. raised its position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 162.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 176,960 shares of the company’s stock after buying an additional 109,585 shares during the quarter. Connor Clark & Lunn Investment Management Ltd.’s holdings in Mirum Pharmaceuticals were worth $7,317,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in MIRM. State Street Corp increased its stake in Mirum Pharmaceuticals by 19.9% in the third quarter. State Street Corp now owns 1,793,728 shares of the company’s stock valued at $69,955,000 after acquiring an additional 297,511 shares during the last quarter. Charles Schwab Investment Management Inc. increased its stake in shares of Mirum Pharmaceuticals by 5.5% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 328,161 shares of the company’s stock valued at $12,798,000 after purchasing an additional 17,149 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Mirum Pharmaceuticals by 3.2% during the 3rd quarter. Geode Capital Management LLC now owns 936,197 shares of the company’s stock worth $36,519,000 after buying an additional 29,017 shares in the last quarter. Hennion & Walsh Asset Management Inc. lifted its position in shares of Mirum Pharmaceuticals by 25.5% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 145,599 shares of the company’s stock worth $6,021,000 after buying an additional 29,545 shares during the last quarter. Finally, Golden State Equity Partners boosted its stake in Mirum Pharmaceuticals by 1,390.8% in the fourth quarter. Golden State Equity Partners now owns 19,380 shares of the company’s stock valued at $801,000 after buying an additional 18,080 shares in the last quarter.

Mirum Pharmaceuticals Trading Down 0.6 %

MIRM opened at $44.28 on Friday. The company has a debt-to-equity ratio of 1.33, a current ratio of 3.34 and a quick ratio of 3.15. Mirum Pharmaceuticals, Inc. has a fifty-two week low of $23.14 and a fifty-two week high of $54.23. The company’s 50 day moving average price is $47.47 and its two-hundred day moving average price is $43.57. The firm has a market capitalization of $2.17 billion, a price-to-earnings ratio of -21.92 and a beta of 1.04.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings data on Wednesday, February 26th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.22). The business had revenue of $99.41 million during the quarter, compared to the consensus estimate of $96.64 million. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. As a group, research analysts predict that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current year.

Insider Buying and Selling at Mirum Pharmaceuticals

In other news, Director Patrick J. Heron acquired 1,335 shares of Mirum Pharmaceuticals stock in a transaction dated Tuesday, March 4th. The shares were bought at an average cost of $45.57 per share, with a total value of $60,835.95. Following the purchase, the director now owns 163,643 shares in the company, valued at $7,457,211.51. This trade represents a 0.82 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, COO Peter Radovich sold 1,998 shares of the stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $42.82, for a total transaction of $85,554.36. Following the sale, the chief operating officer now owns 27,015 shares of the company’s stock, valued at approximately $1,156,782.30. This trade represents a 6.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 40,915 shares of company stock worth $1,897,920. Insiders own 22.87% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently commented on MIRM. HC Wainwright increased their target price on shares of Mirum Pharmaceuticals from $66.00 to $72.00 and gave the stock a “buy” rating in a report on Friday, February 28th. Robert W. Baird increased their price objective on shares of Mirum Pharmaceuticals from $50.00 to $55.00 and gave the company an “outperform” rating in a research note on Thursday, February 27th. Ten analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Mirum Pharmaceuticals presently has an average rating of “Buy” and an average target price of $58.20.

Mirum Pharmaceuticals Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.